Active Ingredient: Tafamidis
Tafamidis is indicated for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
For this indication, competent medicine agencies globally authorize below treatments:
Oral
20 - 20 mg
From 20 To 20 mg once every day
The recommended dose of tafamidis meglumine is 20 mg orally once daily.
Tafamidis and tafamidis meglumine are not interchangeable on a per mg basis.
If vomiting occurs after dosing, and the intact tafamidis capsule is identified, then an additional dose of tafamidis should be administered if possible. If no capsule is identified, then no additional dose is necessary, with resumption of dosing the next day as usual.
Tafamidis may be taken with or without food.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
